A Clinical Study to find out safety and efficacy of Unani drugs in Childhood Psoriasis

A Clinical Study to evaluate the safety and efficacy of Unani Formulations in Childhood Psoriasis - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/075001

Enrollment

Registered

2024-10-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L408- Other psoriasis

Interventions

Intervention1: Habb e Surkhbada, Paste of Sang e Jarahat and Murdaar Sang with Roghan e Babchi: Habb e Surkhbada: 1-2 pill(s) twice daily orally and paste of Sang e Jarahat and Murdaar Sang with Rogha

Eligibility

Inclusion criteria

Inclusion criteria: 1. PASI (Psoriasis Area and Severity Index) score more than 10 2. PGA (Physicians Global Assessment) score: 3–4. 3. BSA is more than 10%. 4. A clinically stable patient. 5. Patients up to 15 years of age. 6. Patients of either sex. 7. Patients are not on any concomitant therapy. 8. Patients who have left the treatment at least 2 months ago. 9. The patient or guardian agreed and signed the written consent proforma.

Exclusion criteria

Exclusion criteria: 1. Doubtful cases of childhood psoriasis. 2. Childhood psoriasis with secondary infection. 3. Immunocompromised patients. 4. Patients above the age of 15 years.

Design outcomes

Primary

Measure	Time frame
Improvement in PASI SCORE, PGA SCORE, BSA involvedTimepoint: Monthly assessment for 6 months +2 months follow up.	—

Secondary

Measure	Time frame
Improvement in itching erythema indurationTimepoint: Monthly assessment for 6 months plus two months follow up	—

Countries

India

Contacts

Public ContactHafsa Tariq

Ajmal Khan Tibbiya College

aqdas2005@gmail.com9412329198

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026